NASDAQ:ONCY

Oncolytics Biotech Stock Insider Trading

Healthcare > Biotechnology

Buy ONCY

*Your capital is at risk

$0.88

-0.0476 (-5.13%)

At Close: Jun 03, 2026

Oncolytics Biotech Stock Insider Power

Based on the 87 latest insides trades, we have calculated the insider power to be positive at 100.00. In total, the insiders bought 10.39M and sold 0 ONCY shares in the last 87 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 87 transactions)	100.00
● Buy	10.39M shares
● Sell	0 shares
100% Buy Activity Negligible or No Correlation
No Significant Signals No statistically significant buy or sell signals detected in recent insider data.

Historical Insider Trades

Date	Type	Person	Role	Amount
Mar 12, 2026 Buy	Common Shares P-Purchase	Kelly Jared Chief Executive Officer	CEO / President	5 050 Value: $5K
Mar 11, 2026 Buy	Common Shares P-Purchase	Parsons James T. Director	Director	10 000 Value: $10.3K
Feb 12, 2026 Buy	Common Shares P-Purchase	Andrews Patricia S Director	Director	35 400 Value: $30.3K
Feb 12, 2026 Buy	Common Shares P-Purchase	Seizinger Bernd R. Director	Director	40 000 Value: $33.9K
Feb 12, 2026 Buy	Common Shares P-Purchase	Hagerman Allison Vp, Product Development	Officer	10 000 Value: $8K
Feb 12, 2026 Buy	Common Shares P-Purchase	Brown Deborah Margaret Director	Director	25 000 Value: $21.2K
Feb 12, 2026 Buy	Common Shares P-Purchase	Heineman Thomas Charles Chief Medical Officer	Officer	12 132 Value: $10.0K
Feb 12, 2026 Buy	Common Shares P-Purchase	Pisano Wayne Director	Director	30 000 Value: $25.3K
Feb 12, 2026 Buy	Common Shares P-Purchase	Look Kirk Chief Financial Officer	C-Suite Officer	12 000 Value: $10.1K
Feb 12, 2026 Buy	Common Shares P-Purchase	Kelly Jared Chief Executive Officer	CEO / President	29 500 Value: $24.8K
Feb 11, 2026 Buy	Common Shares P-Purchase	Aromando Andrew Chief Business Officer	Officer	29 600 Value: $25.4K
Feb 11, 2026 Buy	Common Shares P-Purchase	Seizinger Bernd R. Director	Director	60 000 Value: $49.6K
Feb 11, 2026 Buy	Common Shares P-Purchase	Kelly Jared Chief Executive Officer	CEO / President	5 600 Value: $5K
Jan 16, 2026 Buy	Common Shares P-Purchase	Seizinger Bernd R. Director	Director	100 000 Value: $103.8K
Jan 01, 2026 Buy	Stock Option	Kelly Jared Chief Executive Officer	CEO / President	450 000 Value: $486.0K
Jan 01, 2026 Buy	Stock Option	Kelly Jared Chief Executive Officer	CEO / President	350 000 Value: $346.5K
Jan 01, 2026 Buy	Common Shares	Hagerman Allison Vp, Product Development	Officer	0 Value: $0
Jan 01, 2026 Buy	Stock Option	Hagerman Allison Vp, Product Development	Officer	7 894 Value: $21.0K
Jan 01, 2026 Buy	Stock Option	Hagerman Allison Vp, Product Development	Officer	45 000 Value: $153.0K
Jan 01, 2026 Buy	Stock Option	Hagerman Allison Vp, Product Development	Officer	80 000 Value: $184.8K
Jan 01, 2026 Buy	Stock Option	Hagerman Allison Vp, Product Development	Officer	21 700 Value: $59.9K
Jan 01, 2026 Buy	Stock Option	Hagerman Allison Vp, Product Development	Officer	72 800 Value: $139.0K
Jan 01, 2026 Buy	Stock Option	Hagerman Allison Vp, Product Development	Officer	75 600 Value: $85.4K
Jan 01, 2026 Buy	Stock Option	Hagerman Allison Vp, Product Development	Officer	240 000 Value: $259.2K
Jan 01, 2026 Buy	Stock Option	Hagerman Allison Vp, Product Development	Officer	250 000 Value: $247.5K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT ONCOLYTICS BIOTECH INC.

Oncolytics Biotech Inc., a development-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an intravenously delivered immunotherapeutic agent for the treatment of solid tumors and hematological malignancies. Oncolytics Biotech Inc. has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with ...

Read Full Profile Here